Galderma has shared positive two-year data for its monoclonal antibody Nemluvio (nemolizumab) in moderate-to-severe atopic dermatitis.

The ARCADIA long-term extension (LTE) study has been evaluating the drug in over 1,900 patients who either completed the initial or maintenance period in ARCADIA 1 or 2, or were newly enrolled as adolescents.

Results presented at this year’s Revolutionizing Atopic Dermatitis Conference demonstrated that Nemluvio led to sustained and increased improvements in skin lesions, itch, sleep and quality of life.

The interim analysis showed that, at week 104, more than 85% of evaluable patients achieved a 75% reduction in the Eczema Area and Severity Index (EASI), while approximately 85% and 70% achieved at least a four-point improvement in itch and were itch free or nearly itch free, respectively, assessed by the SCORAD VAS Pruritus score.

At the same time point, around 60% of patients reached clearance or almost-clearance of skin lesions, as measured by the Investigator’s Global Assessment score, and patients’ quality of life improved over time, according to the Dermatology Life Quality Index.

Galderma added that the results “reinforce Nemluvio’s rapid onset of action” on itch and skin at week four. Among patients who had not received Nemluvio before entering the LTE, 49%
achieved a 75% reduction in the EASI, and 69% achieved at least a four-point improvement in itch.

Affecting more than 230 million people worldwide, atopic dermatitis is a chronic inflammatory skin disease characterised by persistent itch and recurrent skin lesions.

Nemluvio, which was initially developed by Chugai Pharmaceutical, is designed to address the underlying cause of the disorder by inhibiting signalling of the neuroimmune cytokine IL-31. The drug already holds approvals to treat certain cases of atopic dermatitis and prurigo nodularis, another chronic skin condition.

Galderma holds exclusive rights to the development and marketing of nemolizumab everywhere except Japan, where it is marketed as Mitchga.